Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Medicago
Medicago
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Design & Build
Medicago contributes CA$500,000 to help establish Class 3 containment laboratory at Université Laval
Remaining two-thirds of the funds will be provided by the City of Quebec and the research centre's foundation
Research & Development
Medicago to develop Ebola monoclonal antibodies for the Canadian government
Plant-based antibodies to be developed in mini-factories to fight the Sudan strain of the Ebola virus
Manufacturing
Medicago to build C$245m vaccine production facility in Quebec City, Canada
Will create 200 new highly skilled jobs by 2019
Finance
Mitsubishi Tanabe Pharma to acquire Medicago for $357m
Medicago has been collaborating with MTPC since 2012 to develop and commercialise rotavirus VLP-based vaccines
Manufacturing
Medicago produces rotavirus VLP vaccine candidate
It comprises all four structural antigens of rotavirus using its plant-based manufacturing platform
Research & Development
Medicago and Mitsubishi to develop next generation technology for plant production
Companies to evaluate closed hydroponic Plant Factory System
Research & Development
Canadian government awards US$493,000 to Medicago
To support development of new potency assays and process analytical technologies
Subscribe now